The Journal of Bioprocess Technology has published a paper co-authored by Nascent Biologics Inc. co-founder and chief executive officer Dr. Mark C. Glassy, PhD, entitled “Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line.” This study highlights NBI’s relationship with Catalent, detailed here.
From the paper’s abstract:
Expression of many therapeutic antibodies is not always cost effective due to low level of secretion per cell per day; thus, goal of the present investigations was to determine if the GPEx® technology developed by the Catalent Pharma Solutions could overcome this limitation for the pritumumab. Pritumumab is a natural human IgG1 kappa antibody isolated from a lymph node of a patient with cervical carcinoma. The original human-human hybridoma secreted approximately 1 picogram of antibody per cell per day (pcd). To circumvent this limitation, and to make the antibody more commercially viable, a pritumumab-secreting Chinese Hamster Ovary (CHO) cell line was created using the GPEx® technology. A number of the resulting clones secreted greater than 40 pcd – at least a 40-fold increase over the original human-human hybridoma. Comparison of immunoreactivity of pritumumab produced by the two methods by flow cytometry binding and immunohistochemical staining of tumor tissues revealed them to be comparable. In conclusion, it is clear that application of the GPEx® technology for high level of therapeutic antibody (pritumumab) represents a significant advancement towards its production in a cost effective manner, and circumvents the limitation of low rate of expression for application in therapy and diagnosis of cancer.